Groundbreaking results in advanced melanoma treatment are emerging! A personalized vaccine, EVX-01, when combined with pembrolizumab, is showing remarkable promise in controlling the disease and triggering lasting immune responses. This combination therapy has achieved an impressive 75% overall response rate (ORR), indicating significant tumor reduction in patients. But how does it work, and what does this mean for the future of melanoma treatment?
This information comes from a phase 2 trial (NCT05309421) with a 2-year follow-up presented at the 2025 ESMO Congress. The results are compelling: responses were sustained in 11 out of 12 responders after two years. While some patients did discontinue the study due to disease progression or complications, the overall durability of the responses is a key highlight. Furthermore, deepened responses were observed in a significant portion of patients, with a 54% conversion rate, meaning that some patients saw their condition improve from stable disease or partial response to a more complete response.
Let's break down the key elements of this innovative approach:
- EVX-01: This is a personalized peptide-based neoantigen vaccine, meaning it's designed specifically for each patient based on their unique tumor profile.
- Pembrolizumab (Keytruda): A well-known immunotherapy drug that helps the body's immune system recognize and attack cancer cells.
- The Combination: Together, these therapies aim to boost the immune system's ability to fight melanoma effectively.
The Investigation of EVX-01 in Advanced Melanoma
The study showed that EVX-01 plus pembrolizumab induced an ORR of 75% in evaluable patients with stage III/IV unresectable melanoma, along with potent and sustained T-cell responses. The FDA has granted fast track designation to this combination.
The study's lead author, Dr. Adnan Khattak, emphasized the potent and specific T-cell responses seen in all patients. Impressively, an AI Immunology platform accurately predicted these responses at an 81% rate, based on the identification of immunogenic and non-immunogenic vaccine neoantigens. The T-cell responses, triggered by EVX-01, were sustained throughout the first two years of the study.
Why is EVX-01 Being Investigated?
Even with advancements in immunotherapy, there's still a significant unmet need for effective treatments in advanced melanoma. EVX-01 addresses this by creating a personalized vaccine tailored to each patient's tumor. This is achieved through:
- DNA and RNA Sequencing: Analyzing patient blood and tumor samples.
- AI Immunology Platform: Identifying 7-10 patient-specific antigens that are optimal for each individual.
- Peptide and EVX-01 Formulation: Creating the personalized vaccine.
How Was the Phase 2 Trial Designed?
The phase 2 trial included patients with advanced melanoma who were not suitable for local therapy. Key aspects of the trial design included:
- Eligibility: Patients aged 18+ with confirmed metastatic or unresectable stage III/IV melanoma.
- Exclusions: Patients with uveal or ocular melanoma or prior treatment with immune checkpoint inhibitors were excluded.
- BRAF Status: BRAF mutation testing was required.
- Treatment: All patients received pembrolizumab every 6 weeks, alongside the personalized EVX-01 vaccine.
- Vaccine Schedule: Priming doses of EVX-01 were administered over several weeks, followed by booster doses over two years. The manufacturing success rate for EVX-01 was 100%.
- Endpoints: The study focused on ORR, duration of response, and conversion rate.
The patient population was predominantly White, male, and at least 65 years old. A majority had stage IV disease and normal LDH levels.
Safety Data at 2 Years
Regarding toxicities specific to EVX-01, no grade 3 or higher adverse effects (AEs) were reported. The combination therapy was linked to grade 3 pancreatitis and grade 4 diabetic ketoacidosis in 1 patient.
But here's where it gets controversial... The use of personalized vaccines is still a relatively new approach. What are the long-term effects of this combination therapy? Are there any potential side effects that we should be concerned about?
And this is the part most people miss... The study's findings are promising, but it's important to remember that this is a phase 2 trial. More research is needed to confirm these results and understand the full potential of EVX-01 in combination with pembrolizumab.
What are your thoughts on this innovative approach to melanoma treatment? Do you believe personalized vaccines are the future of cancer therapy? Share your opinions in the comments below!
